Savolitinib
- Generic Name
- Savolitinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C17H15N9
- CAS Number
- 1313725-88-0
- Unique Ingredient Identifier
- 2A2DA6857R
- Background
Savolitinib has been used in trials studying the treatment and health services research of Tumor, Food Effect, Gastric Cancer, Health Subjects, and Colorectal Cancer, among others.
- Indication
用于含铂化疗后疾病进展或不耐受标准含铂化疗的、具有间质-上皮转化因子（MET）外显子14跳变的局部晚期或转移性非小细胞肺癌成人患者。
- Associated Conditions
- -
- Associated Therapies
- -
Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS
- Conditions
- Interventions
- Drug: Albumin-Bound PaclitaxelDrug: OtherDrug: EpirubicinDrug: GemcitabineDrug: VinorelbineDrug: CisplatinDrug: IrinotecanDrug: FluorouracilDrug: NivolumabDrug: PembrolizumabDrug: DurvalumabDrug: AtezolizumabDrug: SintilimabDrug: TislelizumabDrug: CamrelizumabDrug: ToripalimabDrug: SerplulimabDrug: AdebrelimabDrug: EnvafolimabDrug: OsimertinibDrug: AlectinibDrug: VemurafenibDrug: PamiparibDrug: PyrotinibDrug: ImatinibDrug: PalbociclibDrug: SavolitinibDrug: Entrectinib
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Peking University Shenzhen Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT06692491
Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.
- First Posted Date
- 2024-08-21
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 120
- Registration Number
- NCT06563999
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Positron-emission Tomography Study to Determine Brain Exposure of [11C]Savolitinib in Healthy Volunteers
- First Posted Date
- 2024-04-04
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 7
- Registration Number
- NCT06348355
- Locations
- 🇸🇪
Research Site, Solna, Sweden
A Study to Assess the Effects of Fluvoxamine on Savolitinib Exposure in Healthy Male Subjects
- First Posted Date
- 2023-06-05
- Last Posted Date
- 2023-08-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 16
- Registration Number
- NCT05888207
- Locations
- 🇺🇸
Research Site, Brooklyn, Maryland, United States
Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression
- First Posted Date
- 2023-03-21
- Last Posted Date
- 2023-10-10
- Target Recruit Count
- 29
- Registration Number
- NCT05777278
- Locations
- 🇨🇳
Department of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
A Study to Assess the Effects of Savolitinib on the Pharmacokinetics of Digoxin, Rosuvastatin, Metformin, and Furosemide in Healthy Male Subjects
- Conditions
- Interventions
- First Posted Date
- 2023-03-14
- Last Posted Date
- 2023-07-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 6
- Registration Number
- NCT05768360
- Locations
- 🇩🇪
Research Site, Berlin, Germany
Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)
- Conditions
- Interventions
- First Posted Date
- 2022-11-17
- Last Posted Date
- 2023-01-11
- Lead Sponsor
- Jeeyun Lee
- Target Recruit Count
- 25
- Registration Number
- NCT05620628
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC
- First Posted Date
- 2022-05-16
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 47
- Registration Number
- NCT05374603
- Locations
- 🇨🇳
Research Site, Zhengzhou, China
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
- Conditions
- Interventions
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 324
- Registration Number
- NCT05261399
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC
- Conditions
- Interventions
- First Posted Date
- 2021-12-20
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 44
- Registration Number
- NCT05163249
- Locations
- 🇨🇳
Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.